The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients

ALK missense mutations are detected in 8% of neuroblastoma (NB) tumors at diagnosis and confer gain-of-function oncogenic effects. The mechanisms by which the expression of wild-type or mutant ALK, which is detectable in the majority of cases, is regulated are not well understood. We have identified...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshareef, Abdulraheem, Irwin, Meredith S., Gupta, Nidhi, Zhang, Hai-Feng, Haque, Moinul, Findlay, Scott D., Seong, Bo Kyung Alex, Lai, Justine, Rayis, Mohammed, Al-Dandan, Sadeq, Lai, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828214/
https://www.ncbi.nlm.nih.gov/pubmed/29535836
http://dx.doi.org/10.18632/oncotarget.24216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828214/
https://www.ncbi.nlm.nih.gov/pubmed/29535836
http://dx.doi.org/10.18632/oncotarget.24216

Ejemplares similares